These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22281594)

  • 1. Drug discovery: Chemical beauty contest.
    Leeson P
    Nature; 2012 Jan; 481(7382):455-6. PubMed ID: 22281594
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies for success in drug development.
    Wardell WM
    Retina; 2005 Dec; 25(8 Suppl):S100-S102. PubMed ID: 16374309
    [No Abstract]   [Full Text] [Related]  

  • 3. An overview of automated systems relevant in pharmaceutical salt screening.
    Kumar L; Amin A; Bansal AK
    Drug Discov Today; 2007 Dec; 12(23-24):1046-53. PubMed ID: 18061884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery.
    Kennedy D
    Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
    [No Abstract]   [Full Text] [Related]  

  • 5. Lead-oriented synthesis: a new opportunity for synthetic chemistry.
    Nadin A; Hattotuwagama C; Churcher I
    Angew Chem Int Ed Engl; 2012 Jan; 51(5):1114-22. PubMed ID: 22271624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From molecule to medicine--drug development].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
    [No Abstract]   [Full Text] [Related]  

  • 7. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association.
    Chetty RK; Ozer JS; Lanevschi A; Schuppe-Koistinen I; McHale D; Pears JS; Vonderscher J; Sistare FD; Dieterle F
    Clin Pharmacol Ther; 2010 Aug; 88(2):260-2. PubMed ID: 20592723
    [No Abstract]   [Full Text] [Related]  

  • 8. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimation of the shelf-life of drugs with mixed effects models.
    Chen JJ; Hwang JS; Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):131-40. PubMed ID: 7613558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy: the role of chemistry, manufacturing, and controls in pharmaceutical drug development.
    DiFeo TJ
    Drug Dev Ind Pharm; 2004 Mar; 30(3):247-57. PubMed ID: 15109024
    [No Abstract]   [Full Text] [Related]  

  • 11. Meeting the demands of regulatory requirements: the significance of ADME.
    Guttendorf R
    Bioanalysis; 2012 Jun; 4(12):1395-7. PubMed ID: 22793021
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergies of virtual screening approaches.
    Muegge I
    Mini Rev Med Chem; 2008 Aug; 8(9):927-33. PubMed ID: 18691150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for reform of the IND/NDA processes: part II.
    Romansky MA
    J Clin Psychopharmacol; 1982 Dec; 2(6):424-6. PubMed ID: 7174868
    [No Abstract]   [Full Text] [Related]  

  • 14. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
    Raman NV; Prasad AV; Ratnakar Reddy K
    J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?
    Ivanenkov YA; Zagribelnyy BA; Aladinskiy VA
    J Med Chem; 2019 Nov; 62(22):10026-10043. PubMed ID: 31188596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hierarchical screening methodology for physicochemical/ADME/Tox profiling.
    DeWitte RS; Robins RH
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):805-17. PubMed ID: 17014396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and novel strategies in pre-clinical formulation development: an overview.
    Shah AK; Agnihotri SA
    J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the scope of crystal form evaluation in pharmaceutical science.
    Peterson ML; Hickey MB; Zaworotko MJ; Almarsson O
    J Pharm Pharm Sci; 2006; 9(3):317-26. PubMed ID: 17207415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of microarrayed compound screening.
    Hoever M; Zbinden P
    Drug Discov Today; 2004 Apr; 9(8):358-65. PubMed ID: 15081963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.